Droxicam

Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253) . Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse[1][2].

Product Specifications

CAS Number

[90101-16-9]

Product Name Alternative

Ombolan

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/droxicam.html

Purity

99.59

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N1C2=CC=CC=N2)C(N3C)=C(OC1=O)C4=C(C=CC=C4)S3(=O)=O

Molecular Formula

C16H11N3O5S

Molecular Weight

357.34

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Farré AJ, et al. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find Exp Clin Pharmacol. 1986 Jul;8 (7) :407-22. |[2]Jané F, et al. Droxicam: a pharmacological and clinical review of a new NSAID. Eur J Rheumatol Inflamm. 1991;11 (4) :3-9.